Home > Healthcare > Pharmaceuticals > Clinical Nutrition > Intravenous Solutions Market

Intravenous Solutions Market Share

Report ID: GMI8359
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Intravenous Solutions Market Share

The competitive landscape of the market is characterized by the presence of established pharmaceutical companies vying for market share. Key players are engaging in strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their product portfolios. The companies are actively adopting a multi-pronged approaches to address the rising demand for effective intravenous solutions.

Intravenous Solutions Market Companies

Prominent players operating in the intravenous solutions industry are as mentioned below:

Ajinomoto Co., Inc.
Amanta Healthcare
Axa Parenterals Ltd
B. Braun Melsungen AG
Baxter International Inc.
Fresenius Kabi USA, LLC
Grifols, S.A.
ICU Medical. Inc
JW Life Science
Otsuka Pharmaceutical Co., Ltd
Pfizer, Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Intravenous solutions industry size was USD 13 billion in 2023 and is expected to reach USD 24.8 billion by 2032, driven by the growing geriatric population, increasing cases of malnutrition, and high prevalence of preterm births.

The total parenteral nutrition type segment reached a revenue of USD 8.7 billion in 2023 and will grow significantly through 2032, due to its role in providing complete nutrition to patients who cannot consume food orally.

North America recorded 42.7% of the intravenous solutions industry share in 2023 and is expected to dominate throughout 2024 and 2032 attributed to the advanced healthcare infrastructure in the region, a strong focus on patient care, and high healthcare expenditure.

Ajinomoto Co., Inc., Amanta Healthcare, Axa Parenterals Ltd, B. Braun Melsungen AG, Baxter International Inc., Fresenius Kabi USA, LLC, Grifols, S.A., ICU Medical. Inc., JW Life Science, Otsuka Pharmaceutical Co., Ltd, and Pfizer, Inc.